论文信息 - Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer - 字舞流文

Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer

W. Scheithauer | L. Saltz | S. Clarke | A. Figer | M. Lichinitser | J. Cassidy | E. Díaz-Rubio | S. Koski | R. Wong | T. Yang | T. Yang | T. Yang